Altered interleukin‐2 receptor <i>α</i>‐chain is expressed in human T‐cell leukaemia virus type‐I‐infected T‐cell lines and human peripheral blood mononuclear cells of adult T‐cell leukaemia patients through an alternative splicing mechanism

Horiuchi, Sankichi; Koyanagi, Yoshio; Tanaka, Yoshiya; Waki, Michinori; Matsumoto, Akihiro; Zhou, Yongwei; Yamamoto, Mikio; Yamamoto, Naoki

doi:10.1046/j.1365-2567.1997.00236.x

Cited by 20 publications

(19 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increased expression of pre-mRNA processing genes, such as SRPK1, and altered splicing of gene products may contribute to pathogenesis for some of the tumour. Notably, the altered splicing patterns of IL-2 receptor (Horiuchi et al, 1997), Fas (Sugahara et al, 1997), MEL1 (Yoshida et al, 2004) and HTLV-I pX genes (Berneman et al, 1992) were reported. Such alternative splicing events may be associated with the overexpression of SRPK1.…”

Section: Discussionmentioning

confidence: 99%

Serological identification of adult T‐cell leukaemia‐associated antigens

et al. 2005

View full text Add to dashboard Cite

SummaryAdult T-cell leukaemia (ATL) is a peripheral T-cell neoplasm caused by human T-cell leukaemia virus type I (HTLV-I). Several clinical observations suggest that some tumour-associated antigens in ATL may be recognised by the immune system. In this study, we performed the serological screening of an expression library to identify ATL-associated antigens by using materials from a unique ATL patient with long-term stable disease. Among five distinct genes isolated, serine/arginine protein kinase 1 (SRPK1), which has been reported to have a restricted normal tissue distribution, was found to be overexpressed in most acute type ATL samples, but not in chronic type ATL or in normal peripheral blood mononuclear cells by real-time reverse transcription polymerase chain reaction. Interestingly, the overexpression of SRPK1 in aggressive types of ATL was more exclusively observed at the protein level than at the mRNA level. Autologous antibody to SRPK1 was confirmed in the ATL patient using Western blot analysis with plasma, but not detected in asymptomatic HTLV-I carriers or in healthy volunteers. These results indicate that SRPK1 may be useful for the development of therapeutic and diagnostic methods for patients with ATL.

show abstract

Section: Discussionmentioning

confidence: 99%

Serological identification of adult T‐cell leukaemia‐associated antigens

et al. 2005

View full text Add to dashboard Cite

show abstract

“…The Δ4 protein isoform was further characterized by Neeper et al [47]: Unlike full-length CD25, the Δ4 isoform was incapable of binding IL-2. Horiuchi et al [48] also provided evidence for another alternatively spliced mRNA from IL2RA encoding an isoform lacking the amino acids encoded by exons 5 to 7, which includes the transmembrane region, and is presumably secreted.…”

Section: Il-2/il-2r Transcriptional Regulation: Splicingmentioning

confidence: 98%

The IL-2/CD25 Pathway Determines Susceptibility to T1D in Humans and NOD Mice

Dendrou

Wicker

2008

J Clin Immunol

View full text Add to dashboard Cite

“…Waldmann (20). The receptor is not expressed by resting normal cells while it is overexpressed by a proportion of abnormal cells of lymphoid neoplasia (21), including adult T-cell leukemia (22).…”

Section: Introductionmentioning

confidence: 99%

In vivo efficacy of systemic tumor targeting of a viral RNA vector with oncolytic properties using a bispecific adapter protein

Bian

Wilden²,

Fournier³

et al. 2006

Int J Oncol

View full text Add to dashboard Cite

Abstract. The aim of the study was: i) to specifically target tumor tissue by Newcastle disease virus (NDV) with oncolytic properties, ii) to improve the delivery system for systemic application of NDV via a bispecific adapter protein and iii) to investigate anti-tumor activity and side-effects. We selected two oncolytic virus strains, one native and the other recombinant, which showed multicyclic replication patterns in tumor cells. In order to reduce normal cell binding, they were modified by preincubation with a recombinant bispecific protein which blocks the viral native cell binding site and introduces a new binding site for a tumor-associated target (in this study, the interleukin-2-receptor, IL-2R). After intravenous transfer to mice, uptake of modified NDV in liver, spleen, kidney and lung was greatly reduced in comparison to unmodified NDV as determined by RRT-PCR of viral M gene copies. In IL-2R + tumor bearing mice, the same assay revealed a high replication efficiency of the modified virus in the tumor tissue. Tumor therapy experiments showed that the side-effects induced by systemic application were greatly reduced by the adapter protein and that the anti-tumor effects were mostly undiminished. The demonstration of significant systemic anti-tumor activity of this viral vector suggests potential for augmentation by inclusion of one or more therapeutic genes.

show abstract

Altered interleukin‐2 receptor α‐chain is expressed in human T‐cell leukaemia virus type‐I‐infected T‐cell lines and human peripheral blood mononuclear cells of adult T‐cell leukaemia patients through an alternative splicing mechanism

Cited by 20 publications

References 24 publications

Serological identification of adult T‐cell leukaemia‐associated antigens

Serological identification of adult T‐cell leukaemia‐associated antigens

The IL-2/CD25 Pathway Determines Susceptibility to T1D in Humans and NOD Mice

In vivo efficacy of systemic tumor targeting of a viral RNA vector with oncolytic properties using a bispecific adapter protein

Contact Info

Product

Resources

About